Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy
Clinical Pharmacology & Therapeutics · 2023-10 · 114 (4) · 768-779
DOI: 10.1002/cpt.2978 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 11.07.2023. Verfasst von Daniel L Hertz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Fluorouracil, Dihydrouracil Dehydrogenase (NADP). Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Fluoropyrimidine (FP) chemotherapy is associated with severe, life‐threatening toxicities, particularly among patients who carry deleterious germline variants in the DPYD gene. Pretreatment DPYD testing is standard of care throughout most of Europe; however, it has not been recommended in clinical practice guidelines in the United States. Due to increased risk of severe toxicity, a Citizen's Petition asked the US Food and Drug Administration (FDA) to update language in FP drug labels to recommend DPYD testing as part of a boxed warning and recommend FP dose reduction in patients carrying deleterious germline variants. In response, the FDA updated the capecitabine package insert to inform patients about the toxicity risk and test availability and consider DPYD testing. However, the FDA did not include a testing recommendation or requirement, or a boxed warning. Additionally, the FDA did not recommend FP dose adjustment in DPYD variant carriers. This review provides a critical assessment of the DPYD ‐FP pharmacogenetic association using the FDA's previously published Pharmacogenetic Pyramid, demonstrating that the evidence is compelling for recommending DPYD testing prior to FP treatment. Additionally, the FDA's stated concerns about recommending DPYD testing and DPYD ‐guided FP dose adjustment are addressed and discussed in the context of the FDA's other genetic testing and dose adjustment recommendations. We call on the FDA to follow our European counterparts in recommending DPYD testing and genotype‐based dose adjustment to ensure patients with cancer receive safe and effective FP chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
- Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.
- MedStar Health, Columbia, Maryland, USA.
- Department of Pathology, Stanford University, Stanford, California, USA.
- Clinical Genomics Laboratory, Stanford Medicine, Palo Alto, California, USA.
- Department of Cancer Pharmacology and Pharmacogenomics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
ORCID-Profile: Daniel L Hertz, D Max Smith, Stuart A Scott, Jai N Patel, J Kevin Hicks
Zitieren
APA
Hertz, D. L., Smith, D. M., Scott, S. A., Patel, J. N., & Hicks, J. K. (2023). Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy. Clinical Pharmacology & Therapeutics, 114(4), 768-779. https://doi.org/10.1002/cpt.2978
Vancouver
Hertz DL, Smith DM, Scott SA, Patel JN, Hicks JK. Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy. Clinical Pharmacology & Therapeutics. 2023;114(4):768-779. doi:10.1002/cpt.2978
BibTeX
@article{Hertz2023,
author = {Hertz, Daniel L and Smith, D Max and Scott, Stuart A and Patel, Jai N and Hicks, J Kevin},
title = {Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
volume = {114},
number = {4},
pages = {768--779},
doi = {10.1002/cpt.2978}
}
EUVIMED